Iterum Q3 net loss $29.1M; starts uUTI trial; cash into 2024

Iterum Therapeutics plc

2022-Q3 EPS reported -$3.22

Net loss $29.1M vs income $3.7M YoY; non-GAAP net loss $5.3M.
Cash, equivalents & short-term investments $64.3M; runway into 2024.
R&D expense $4.4M (up from $1.8M) due to REASSURE trial startup.
Enrollment in Phase 3 REASSURE trial for uUTI began Oct 2022; completion expected H1 2024.
New US patent (No. 11,478,428) for oral sulopenem bilayer tablet extends protection to 2039.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-22-024154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.